Qnexa is a new weight loss treatment which incorporates two previously approved drugs in a new formulation. Qnexa has shown superior efficacy over either if it's two components drugs which have both previously been used to treat obesity.
In clinical trials Qnexa has also demonstrated a lower level of side effects than either of it's component active ingredients or other commonly available obesity treatments.
In it's phase two clinical trials Qnexa achieved a weight loss averaging 20 pounds at 24 weeks.http://www.vivus.com/pipeline/qnexa-obesity
In phase 3 clinical trials Qnexa has easily exceeded the FDA's mandated 5% better than placebo weight loss standard showing anaverage weight loss of 14.7%.http://ir.vivus.com/releasedetail.cfm?ReleaseID=407933
On December 29th, 2009 Vivus announced that it had filed a new drug application with the FDA in the United States.http://www.latimes.com/business/nationworld/wire/sns-ap-us-vivus-qnexa,0,4820305.story.
Disclaimer
The content in this page is not a substitute for professional medical advice. Please consult a doctor before taking any action suggested on this page.
References
Fast Facts
-
Structure
A mixture of phentermine and the epilepsy/antidepressant drug topiramate
-
Function
Topiramate works by increases satiety, the feeling of fullness or satisfaction we feel after eating. Phentermine is and amphetamine which reduces appetite.
-
Disorder
Obesity
-
Maunfacturer
Vivus Pharmacutical
